Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
Alderuccio JP, et al. Lancet Haematology. Dec 2024
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Epperla N, et al. Blood Cancer Journal. Nov 2024
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine.
Hamadani M, et al. eJHaem. Sep 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Caimi PF, et al. eJHaem. Nov 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Hamadani M, et al. Blood Advances. Oct 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study
Caimi PF, et al. Haematologica. Aug 2023
Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Chihara D, et al. Blood. June 2023
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Caimi PF, et al. Lancet Oncology. May 2021